论文部分内容阅读
目的 :通过前瞻性对照研究 ,比较VIP方案与MVP方案治疗晚期非小细胞肺癌的疗效及不良反应。方法 :共 5 3例晚期的非小细胞肺癌患者随机入组 ,治疗组应用VIP方案 (VDS +IFO +DDP) ,对照组应用MVP方案 (MMC +VDS +DDP) ,每例病人至少化疗 2疗程。疗效及不良反应评价均按WHO标准进行 ,每例病人随访生存期。结果 :治疗组中 1例CR ,15例PR ,8例SD ,1例PD ,有效率 (CR +PR)为 6 4 0 % ;对照组中 11例PR ,11例SD ,6例PD ,有效率 (CR +PR)为 3 9 3 %。治疗组有效率比对照组高 ,但无统计学差异 (P =0 0 72 )。治疗组中位生存期为 8个月 ,而对照组为 7月 ,两组无差异 (P >0 0 5 ) ,该组资料目前仍在继续进行随访。两组不良反应均主要为骨髓抑制、恶心呕吐、脱发。Ⅲ +Ⅳ的血白细胞下降治疗组为 5 6 0 % ,对照组为 5 0 0 % ,两组无差异 (P>0 0 5 )。结论 :初步的结果显示VIP方案对于非小细胞肺癌的有效性较高 ,可以作为一线方案在临床使用
Objective : To compare the efficacy and adverse reactions of VIP and MVP regimens in the treatment of advanced non-small cell lung cancer by prospective controlled study. METHODS: A total of 53 patients with advanced non-small cell lung cancer were randomly assigned to the study. The treatment group was treated with VIP (VDS + IFO + DDP) and the control group was treated with MVP (MMC + VDS + DDP). Each patient received at least 2 cycles of chemotherapy. . Efficacy and adverse reactions were evaluated according to the WHO criteria, with follow-up survival for each patient. Results: In the treatment group, 1 case of CR, 15 cases of PR, 8 cases of SD and 1 case of PD, the effective rate (CR + PR) was 64.0 %; in the control group 11 cases of PR, 11 cases of SD, 6 cases of PD, there was The efficiency (CR +PR) is 393%. The treatment group was more effective than the control group, but there was no statistical difference (P=0.072). The median survival time was 8 months in the treatment group and 7 months in the control group. There was no difference between the two groups (P > 0 05). The data in this group is still being followed up. Both adverse reactions were mainly myelosuppression, nausea, vomiting and hair loss. III + IV leukopenia treatment group was 506%, the control group was 500%, no difference between the two groups (P> 0 05). Conclusions: Preliminary results show that the VIP regimen is effective for NSCLC and can be used as a first-line regimen in clinical settings.